(c) 2024 PillSync.com

Biktarvy bictegravir 50 mg emtricitabine 200 mg tenofovir alafenamide 25 mg

1 INDICATIONS AND USAGE BIKTARVY is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg: who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir. BIKTARVY is a three-drug combination of bictegravir (BIC), a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg: who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir. ( 1 )

gilead sciences, inc.


3 months ago OVAL BROWN GSI 9883 Biktarvy bictegravir 50 mg emtricitabine 200 mg tenofovir alafenamide 25 mg

OVAL BROWN GSI 9883

3 months ago OVAL BROWN GSI 9883 Biktarvy bictegravir 50 mg emtricitabine 200 mg tenofovir alafenamide 25 mg

GSI 9883 OVAL BROWN

16 HOW SUPPLIED/STORAGE AND HANDLING BIKTARVY tablets are available in bottles and blister packs: Bottle 50 mg/200 mg/25 mg tablets each contain 50 mg of bictegravir (BIC), 200 mg of emtricitabine (FTC), and 25 mg of tenofovir alafenamide (TAF). These tablets are purplish brown, capsule-shaped, and film-coated with "GSI" debossed on one side and "9883" on the other side (NDC 61958-2501-1). 30 mg/120 mg/15 mg tablets each contain 30 mg of BIC,120 mg of FTC, and 15 mg of TAF. These tablets are pink, capsule-shaped, and film-coated with "GSI" debossed on one side and "B" on the other side (NDC 61958-2505-1). 30 mg/120 mg/15 mg tablets each contain 30 mg of BIC,120 mg of FTC, and 15 mg of TAF. These tablets are pink, capsule-shaped, and film-coated with a bisecting score line on one side and "BVY" on the other side (NDC 61958-2506-1). Each bottle contains 30 tablets, a silica gel desiccant, polyester coil, and is closed with a child-resistant closure. Do not remove the desiccant packet. Store bottle below 30 °C (86 °F). Keep bottle tightly closed. Blister Pack 50 mg/200 mg/25 mg tablets each contain 50 mg of BIC, 200 mg of FTC, and 25 mg of TAF. These tablets are purplish brown, capsule-shaped, and film-coated with "GSI" debossed on one side and "9883" on the other side (NDC 61958-2501-3). Each blister pack contains 30 tablets (4 strips each containing 7 tablets and 1 strip containing 2 tablets). Blister packs are sealed with a child-resistant laminated foil lidding material (peel-push), and each blister cavity contains a die-cut desiccant film which is heat staked to the foil lidding material. Store blister pack at 25 °C (77 °F), excursions permitted to 15–30 °C (59–86 °F) (see USP Controlled Room Temperature). Dispense only in original containers.


More pills like OVAL GSI 9883












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site